<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03972748</url>
  </required_header>
  <id_info>
    <org_study_id>47011715.0.0000.5327</org_study_id>
    <nct_id>NCT03972748</nct_id>
  </id_info>
  <brief_title>Use Of Oral Itraconazole In Patients With Locally Limited Basocellular Carcinoma Of Skin.</brief_title>
  <official_title>Evaluation Of The Treatment With Oral Itraconazole In Patients With Basocellular Carcinoma Of Skin, Locally Limited Disease.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hospital de Clinicas de Porto Alegre</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hospital de Clinicas de Porto Alegre</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Patients with localized basocellular carcinoma of the skin, will receive oral Itraconazole,
      200 mg twice daily, for 60 days, prior to curative intent surgery.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients with localized basocellular carcinoma of the skin, will receive oral Itraconazole,
      200 mg once daily, for 60 days, before surgery with curative intent.

      Tumor area regression will be measured through dermatologic evaluation and photographic
      documentation on baseline and at the end of the 60 day treatment period.

      The activity of the Hedgehog pathway will be measured on tissue samples obtained at the time
      of diagnosis and at the time of curative intent surgery, through the measuring of the Ki67
      index.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 5, 2018</start_date>
  <completion_date type="Anticipated">June 1, 2021</completion_date>
  <primary_completion_date type="Anticipated">December 1, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>clinical response</measure>
    <time_frame>60 days</time_frame>
    <description>tumor area response registered through dermatologic evaluation</description>
  </primary_outcome>
  <primary_outcome>
    <measure>hedgehog pathway activity</measure>
    <time_frame>60 days</time_frame>
    <description>Measured through the Ki67 index on pathological specimens at the beginning and at the end of treatment.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">28</enrollment>
  <condition>Basal Cell Carcinoma</condition>
  <condition>Hedgehog Pathway</condition>
  <arm_group>
    <arm_group_label>Itraconazole</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Oral Itraconazole capsules, 200 mg</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Itraconazole 200 mg</intervention_name>
    <description>Oral Itraconazole capsules, 200 mg, twice daily, for 60 days prior to surgery with curative intent.</description>
    <arm_group_label>Itraconazole</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with diagnosis of Basocellular Carcinoma (BCC) of the Skin, histologically
             confirmed.

          -  At least one BCC lesion with 10 mm in the longest diameter

          -  Disease amenable to surgical intervention with curable intent.

          -  Signed Informed Consent

          -  PS ECOG 0 to 3

        Exclusion Criteria:

          -  Chronic renal disease, with a glomerular filtration rate of less than 30 ml/min

          -  Acute or chronic liver disease, as measured by: total bilirubin &gt; than 1.5 x ULN and
             AST and ALT &gt; than 5 x ULN.

          -  Symptomatic cardiac insufficiency or an ejection fraction lower than 50% measured
             through echocardiography,

          -  Other active malignancies in the last year.

          -  Uncontrolled systemic hypertension,

          -  Any chronic infections such as tuberculosis, viral hepatitis and HIV.

          -  Pregnancy, suspected or confirmed.

          -  Known intolerance to the use of Itraconazole.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Renato M Bakos, Ph. D.</last_name>
    <role>Study Chair</role>
    <affiliation>Hospital de Clinicas de Porto Alegre</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Renato M Bakos, Ph. D.</last_name>
    <phone>+555133598000</phone>
    <phone_ext>8619</phone_ext>
    <email>rbakos@hcpa.edu.br</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Rodrigo P Pereira, M.D.</last_name>
    <phone>+555133598000</phone>
    <phone_ext>8619</phone_ext>
    <email>rppereira@hcpa.edu.br</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Hospital de Cl√≠nicas de Porto Alegre</name>
      <address>
        <city>Porto Alegre</city>
        <state>RS</state>
        <zip>90035903</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Renato M Bakos, Ph.D.</last_name>
      <phone>+555133598000</phone>
      <phone_ext>8619</phone_ext>
      <email>rbakos@hcpa.edu.br</email>
    </contact>
  </location>
  <location_countries>
    <country>Brazil</country>
  </location_countries>
  <verification_date>May 2019</verification_date>
  <study_first_submitted>May 31, 2019</study_first_submitted>
  <study_first_submitted_qc>May 31, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">June 4, 2019</study_first_posted>
  <last_update_submitted>May 31, 2019</last_update_submitted>
  <last_update_submitted_qc>May 31, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">June 4, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Itraconazole</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Basal Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Itraconazole</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

